A Phase 1 Study Of Tti-621, A Novel Immune Checkpoint Inhibitor Targeting Cd47, In Subjects With Relapsed Or Refractory Hematologic Malignancies.
JOURNAL OF CLINICAL ONCOLOGY(2016)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY(2016)